A total of 232 normal hematopoietic stem cells (HSCs) and 762 CP-CML stem cells, composed of 255 BCR-ABL+ and 188 BCR-ABL− cells from good responders and 181 BCR-ABL+ and 138 BCR-ABL− cells from poor responders (Table 1), remained in the subsequent analysis. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.